Eli Lilly Speaks Out Against Indiana’s Ban on Most Abortions

Eli Lilly Speaks Out Against Indiana’s Ban on Most Abortions #Eli #Lilly #Speaks #Indianas #Ban #Abortions Welcome to Lopoid

Eli Lilly

LLY -1.46%

& Co. spoke out against Indiana’s new abortion law, saying the restrictions could hurt the pharmaceutical company’s ability to keep and attract employees and will lead it to plan more hiring outside the state.

The Saturday statement came after Indiana’s governor on Friday signed a near-total ban on abortions shortly after lawmakers approved it. The ban takes effect Sept. 15 and includes exceptions.

Lilly, based in Indianapolis, said the company is concerned the law will impact its ability to attract “diverse scientific, engineering and business talent from around the world.” The company, with a market capitalization of $292 billion, is one of the biggest employers in Indiana, with more than 10,000 of its approximately 37,000 global workers in the state.

Calling abortion a “divisive and deeply personal issue,” the company said it has expanded its health-plan coverage to include travel for reproductive services unavailable locally. Many businesses have made similar adjustments since the U.S. Supreme Court in June said abortion wasn’t a constitutional right.

Abortion-rights supporters in Kansas celebrated after a constitutional amendment that would have ended protections for abortion was rejected. It was the first referendum on the issue since the Supreme Court eliminated abortion rights at the federal level. Photo: Tammy Ljungblad/Associated Press

But Lilly said Saturday such efforts “may not be enough for some current and potential employees,” according to the statement. “Given this new law, we will be forced to plan for more employment growth outside our home state.”

The statement, which also suggested the law could hurt recruitment of talent to Indiana broadly, is one of the strongest to date from a big business on the implications of abortion policy. A Lilly spokeswoman declined to comment further.

Indiana is the first state to approve abortion restrictions following the Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision. Other states moved to implement restrictions they had in place in the event that Roe v. Wade, the landmark 1973 decision that established a constitutional right to an abortion, was overturned.

The Supreme Court’s decision to overturn Roe v. Wade has created new questions for employers on how, if at all, to respond to the decision in terms of corporate policies, whether to speak up and what to say. For the last several years, leaders of some of the country’s largest companies have become more vocal on a range of political and social issues, partly due to pressure they have felt from employees.

A number of companies across industries have said they would pay for employees’ travel for abortions or other procedures should they need to go out of state, and some expanded what their health insurance covers as it relates to abortions or reproductive health services more broadly.

Others haven’t made accommodations and have indicated they have no plans to do so.

Indianapolis’s Chamber of Commerce earlier this week said it opposed the state bill, asking lawmakers not to pass it. The chamber flagged concerns about attracting and retaining employees in the state amid workforce shortages, legal risk for doctors, and infant and maternal health issues.

“Over the last two weeks, the Indiana General Assembly has debated a substantial policy change on the issue of abortion in a compressed time frame. Such an expedited legislative process—rushing to advance state policy on broad, complex issues—is, at best, detrimental to Hoosiers, and at worst, reckless,” the chamber said in a statement.

Republican Gov.

Eric Holcomb,

in a statement after he signed the measure, said: “I am personally most proud of each Hoosier who came forward to courageously share their views in a debate that is unlikely to cease any time soon.” He added that he will continue to “keep an open ear.”

Lilly reported its second-quarter earnings last week, with a 4% decline in quarterly revenue, as a drop in sales of the company’s Covid-19 antibody treatment and some older drugs offset gains in sales for newer drugs.

Write to Emily Glazer at emily.glazer@wsj.com

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Click Here To Continue Reading from Source